First-line niraparib is associated with improvement in QA-PFS and QA-TWiST
According to the placebo-controlled trial PRIMA, patients with advanced ovarian cancer seem to benefit from the maintenance therapy with niraparib.
According to the placebo-controlled trial PRIMA, patients with advanced ovarian cancer seem to benefit from the maintenance therapy with niraparib.
Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel, kan du:
Har du allerede en profil?
Log ind
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.